ORKA · XBRL financial data

Oruka Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ORKA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	0	0	—	—
Research and development	4,992	13,832	4,749	1,013	—	100,640
General and administrative	4,774	5,503	5,847	6,283	—	21,411
Total operating expenses	9,766	19,335	10,596	7,296	—	122,051
Operating income (loss)	(9,766)	(19,335)	(10,596)	(7,296)	—	(122,051)
Interest income	—	—	—	—	—	16,630
Interest expense	9	—	—	—	—	—
Other income (expense)	—	—	—	—	—	(12)
Income tax expense (benefit)	(9)	0	0	0	—	—
Net income (loss)	(9,738)	(19,322)	(9,926)	(5,339)	—	(105,433)
Earnings per share, basic USD per share	—	(1.39)	(0.69)	(0.37)	—	—
Earnings per share, diluted USD per share	—	(1.39)	(0.69)	(0.37)	—	—
Weighted average shares, basic thousands of shares	—	13,904	14,410	14,416	—	—
Weighted average shares, diluted thousands of shares	—	13,904	14,410	14,416	—	—

Fiscal years (ORKA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	49,071	53,359	42,445	37,431	61,575	46,935
Marketable securities	—	—	—	—	314,073	290,109
Marketable securities, non-current	—	—	—	—	18,069	142,539
Prepaid and other current assets	—	—	—	—	1,221	6,813
Total current assets	49,968	54,421	42,699	37,592	376,869	343,857
Property and equipment, net	21	48	25	10	162	288
Right-of-use asset	428	437	343	247	876	1,830
Total assets	50,429	54,924	43,085	37,861	396,019	488,617
Accounts payable	1,773	1,117	334	362	—	—
Total current liabilities	3,499	3,498	1,132	637	13,043	15,374
Lease liability, non-current	409	383	280	204	755	1,313
Total liabilities	3,908	3,881	1,412	841	13,798	16,687
Accumulated deficit	(154,154)	(173,476)	(183,402)	(188,741)	(83,724)	(189,157)
Total stockholders' equity	46,521	51,043	41,673	37,020	382,221	471,930
Total liabilities and equity	50,429	54,924	43,085	37,861	396,019	488,617
Common shares outstanding (cover page) thousands of shares	14,410	14,410	14,410	14,501	37,441	49,543

Fiscal years (ORKA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,738)	(19,322)	(9,926)	(5,339)	—	(105,433)
Stock-based compensation	43	497	556	686	—	24,240
Net cash from operating activities	(7,725)	(18,762)	(10,912)	(5,014)	—	(88,210)
Purchases of property and equipment	19	43	2	0	—	209
Net cash from investing activities	(19)	(43)	(2)	0	—	(96,745)
Proceeds from issuing common stock	50,894	24,070	—	—	—	671
Net cash from financing activities	48,452	23,093	0	0	—	170,315
Net change in cash	40,708	4,288	(10,914)	(5,014)	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Oruka Therapeutics	268,470	not reported	(33,145)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17,224	1,418	(18,068)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Cronos Group	467,019	53,007	24,010*	368.4M	—	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36,487	108,019	(62,238)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Capricor Therapeutics	20,935	not reported	(31,485)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269,267	48,971	1,131*	50.6M	—	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	175,700	110,000	100,100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	595	807	(7,169)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	156,512	39,550	9,223*	not reported	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.